(Q45154727)

English

High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM.

scientific article published on 29 January 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

darbepoetin alfa

0 references

quality of life

1 reference

based on heuristic

inferred from title

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

26

object named as

P Fenaux

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

C Kelaidi

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

O Beyne-Rauzy

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

T Braun

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

R Sapena

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

P Cougoul

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

L Adès

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

C Lamberto

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

J C Charniot

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

A Guerci

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

B Choufi

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

A Stamatoullas

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

B Slama

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

B De Renzis

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

S Ame

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

G Damaj

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

F Boyer

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

M P Chaury

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

L Legros

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

S Cheze

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

A Testu

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

M C Béné

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

C Rose

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

F Dreyfus

25

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

29 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Annals of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

92

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

621-631

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23358617%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Proposals for the classification of the myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1686-4

21 January 2018

Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1686-4

21 January 2018

Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1686-4

21 January 2018

Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1686-4

21 January 2018

Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1686-4

21 January 2018

Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1686-4

21 January 2018

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1686-4

21 January 2018

Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1686-4

21 January 2018

Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996).

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1686-4

21 January 2018

Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1686-4

21 January 2018

Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1686-4

21 January 2018

Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1686-4

21 January 2018

High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1686-4

21 January 2018

Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1686-4

21 January 2018

A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1686-4

21 January 2018

Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: efficacy and quality of life.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1686-4

21 January 2018

Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1686-4

21 January 2018

Revised international prognostic scoring system for myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1686-4

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1686-4

21 January 2018

Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1686-4

21 January 2018

An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1686-4

21 January 2018

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1686-4

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45154727&oldid=1313499368"